Drug evaluation: bevirimat--HIV Gag protein and viral maturation inhibitor.

There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

Abstract

Panacos Pharmaceuticals Inc is developing the HIV Gag protein and viral maturation inhibitor bevirimat for the potential oral treatment of HIV infection. Phase II clinical trials are underway and phase III trials expected to commence in 2007.

Related collections

Author and article information

Journal

Journal ID (iso-abbrev): Curr Opin Investig Drugs

Title: Current opinion in investigational drugs (London, England : 2000)

ISSN: 1472-4472

ISSN (Print): 1472-4472

Publication date (Electronic): Aug 2006

Volume: 7

Issue: 8

Affiliations

[1 ] Mayo Clinic, Division of Infectious Diseases, 200 First Street SW, Rochester, MN 55905, USA. temesgen.zelalem@mayo.edu

Article

PubMed ID: 16955688

SO-VID: bfed16f3-ecab-489a-ba25-048aed367f00

History

Data availability:

Comments

Comment on this article

Cited by 3

See all cited by